<p>Pulmonx Corporation (NASDAQ:LUNG - 获取免费报告) 在 12 月份的空头头寸显著增长。截至 12 月 15 日，空头头寸总计为 3,086,595 股，比 11 月 30 日的 2,526,582 股增长了 22.2%。目前，公司 8.0% 的股份被做空。根据平均每日交易量 1,189,881 股，空头头寸比率目前为 2.6 天。</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师对 LUNG 股票发表了看法。华尔街 Zen 在 11 月 16 日的报告中将 Pulmonx 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Pulmonx 的 “卖出（e+）” 评级。D. Boral Capital 在 11 月 13 日的报告中重申了 “买入” 评级，并对 Pulmonx 的目标价设定为 14.00 美元。最后，Lake Street Capital 在 10 月 28 日的研究报告中将 Pulmonx 的目标价从 8.00 美元下调至 4.00 美元，并对该股票设定了 “买入” 评级。五位研究分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Pulmonx 目前的平均评级为 “持有”，平均目标价为 6.81 美元。</p>
<p><strong>查看我们最新的 LUNG 股票分析</strong></p>
<h2>Pulmonx 的机构交易</h2>
<p>一些对冲基金最近增加或减少了在 LUNG 的持股。Parkman Healthcare Partners LLC 在第一季度将其在 Pulmonx 的持股增加了 194.4%。Parkman Healthcare Partners LLC 目前拥有 611,875 股公司股票，价值 4,118,000 美元，在此期间又收购了 404,022 股。Trexquant Investment LP 在第一季度将其在 Pulmonx 的持股增加了 140.0%。Trexquant Investment LP 目前拥有 224,909 股公司股票，价值 1,514,000 美元，在上个季度又购买了 131,209 股。Connor Clark &amp; Lunn Investment Management Ltd.在第二季度将其在 Pulmonx 的持股增加了 32.1%。Connor Clark &amp; Lunn Investment Management Ltd.目前拥有 218,758 股公司股票，价值 567,000 美元，在上个季度又收购了 53,148 股。Fjarde AP Fonden Fourth Swedish National Pension Fund 在第二季度收购了 Pulmonx 的新股份，价值约 197,000 美元。最后，R Squared Ltd 在第二季度购买了 Pulmonx 的新股份，价值约 41,000 美元。91.04% 的股票由机构投资者和对冲基金持有。</p>
<h2>Pulmonx 股票表现</h2>
<p>LUNG 股票在周三的中午交易中下跌 0.07 美元，报 2.21 美元。该股票交易量为 482,764 股，而其平均交易量为 873,781 股。该股票的市值为 9116 万美元，市盈率为-1.57，贝塔系数为 0.22。Pulmonx 的 12 个月低点为 1.31 美元，12 个月高点为 9.37 美元。该股票的 50 日简单移动平均线为 1.96 美元，200 日简单移动平均线为 2.04 美元。公司的债务与股本比率为 0.62，速动比率为 4.15，流动比率为 4.86。</p>
<p>Pulmonx (NASDAQ:LUNG - 获取免费报告) 最近在 11 月 12 日发布了季度财报。公司报告每股收益为-0.34 美元，超出市场共识预期的-0.40 美元 0.06 美元。该季度的营业收入为 2150 万美元，而市场共识预期为 2078 万美元。Pulmonx 的股本回报率为-77.58%，净利润率为-61.91%。分析师平均预测 Pulmonx 在本年度的每股收益为-1.55 美元。</p>
<h2>关于 Pulmonx</h2>
<p>(获取免费报告)</p>
<p>Pulmonx Corporation 是一家商业阶段的医疗设备公司，专注于为严重肺气肿患者提供支气管镜肺容积缩小治疗。公司的旗舰疗法 Zephyr®支气管阀系统采用单向阀，通过微创的支气管镜手术将其送入，以塌陷病变的肺部，减少肺部过度膨胀并改善呼吸功能。作为该治疗的补充，Pulmonx 还提供 Chartis®肺部评估系统，为临床医生提供定量的侧支通气测量，以帮助患者选择并优化临床结果。</p>
<p>Zephyr 阀在 2008 年获得欧洲 CE 标志，2018 年获得美国 FDA 批准，至今已被北美和欧洲的领先呼吸和胸外科中心采用。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Pulmonx</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微小的 “3 美元 AI 奇迹股” 即将爆发</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Pulmonx 吗？</h2>
<p>在你考虑 Pulmonx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Pulmonx 并不在名单上。</p>
<p>虽然 Pulmonx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LUNG

<p>Pulmonx Corporation (NASDAQ:LUNG) 在 12 月份的空头头寸增加了 22.2%，总计达到 3,086,595 股。目前，8.0% 的股份被做空，基于平均每日交易量 1,189,881 股，空头头寸比率为 2.6 天。分析师对该股票的评级不一，平均目标价格为 6.81 美元。机构投资者持有 91.04% 的股份。Pulmonx 的股票交易价格为 2.21 美元，市值为 9116 万美元，最近的季度财报显示收入为 2150 万美元</p>

<p>Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 3,086,595 shares, a growth of 22.2% from the November 30th total of 2,526,582 shares. Currently, 8.0% of the company's shares are short sold. Based on an average daily trading volume, of 1,189,881 shares, the short-interest ratio is presently 2.6 days. Based on an average daily trading volume, of 1,189,881 shares, the short-interest ratio is presently 2.6 days. Currently, 8.0% of the company's shares are short sold.</p>
<div class="lb-trans"><p>Pulmonx Corporation (NASDAQ:LUNG - 获取免费报告) 在 12 月份的空头头寸显著增长。截至 12 月 15 日，空头头寸总计为 3,086,595 股，比 11 月 30 日的 2,526,582 股增长了 22.2%。目前，公司 8.0% 的股份被做空。根据平均每日交易量 1,189,881 股，空头头寸比率目前为 2.6 天。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts have weighed in on LUNG shares. Wall Street Zen upgraded shares of Pulmonx from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Pulmonx in a research note on Wednesday, October 8th. D. Boral Capital reiterated a &#34;buy&#34; rating and issued a $14.00 target price on shares of Pulmonx in a report on Thursday, November 13th. Finally, Lake Street Capital cut their price target on shares of Pulmonx from $8.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, October 28th. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pulmonx currently has an average rating of &#34;Hold&#34; and an average price target of $6.81.</p>
<div class="lb-trans"><p>几位股票分析师对 LUNG 股票发表了看法。华尔街 Zen 在 11 月 16 日的报告中将 Pulmonx 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Pulmonx 的 “卖出（e+）” 评级。D. Boral Capital 在 11 月 13 日的报告中重申了 “买入” 评级，并对 Pulmonx 的目标价设定为 14.00 美元。最后，Lake Street Capital 在 10 月 28 日的研究报告中将 Pulmonx 的目标价从 8.00 美元下调至 4.00 美元，并对该股票设定了 “买入” 评级。五位研究分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Pulmonx 目前的平均评级为 “持有”，平均目标价为 6.81 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on LUNG</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LUNG 股票分析</strong></p>
</div><h2>Institutional Trading of Pulmonx</h2>
<div class="lb-trans"><h2>Pulmonx 的机构交易</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in LUNG. Parkman Healthcare Partners LLC lifted its stake in shares of Pulmonx by 194.4% in the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company's stock worth $4,118,000 after acquiring an additional 404,022 shares during the period. Trexquant Investment LP boosted its position in shares of Pulmonx by 140.0% in the 1st quarter. Trexquant Investment LP now owns 224,909 shares of the company's stock worth $1,514,000 after buying an additional 131,209 shares in the last quarter. Connor Clark &amp; Lunn Investment Management Ltd. grew its stake in Pulmonx by 32.1% in the 2nd quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 218,758 shares of the company's stock valued at $567,000 after acquiring an additional 53,148 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in Pulmonx in the 2nd quarter valued at about $197,000. Finally, R Squared Ltd purchased a new stake in shares of Pulmonx in the second quarter valued at about $41,000. 91.04% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金最近增加或减少了在 LUNG 的持股。Parkman Healthcare Partners LLC 在第一季度将其在 Pulmonx 的持股增加了 194.4%。Parkman Healthcare Partners LLC 目前拥有 611,875 股公司股票，价值 4,118,000 美元，在此期间又收购了 404,022 股。Trexquant Investment LP 在第一季度将其在 Pulmonx 的持股增加了 140.0%。Trexquant Investment LP 目前拥有 224,909 股公司股票，价值 1,514,000 美元，在上个季度又购买了 131,209 股。Connor Clark &amp; Lunn Investment Management Ltd.在第二季度将其在 Pulmonx 的持股增加了 32.1%。Connor Clark &amp; Lunn Investment Management Ltd.目前拥有 218,758 股公司股票，价值 567,000 美元，在上个季度又收购了 53,148 股。Fjarde AP Fonden Fourth Swedish National Pension Fund 在第二季度收购了 Pulmonx 的新股份，价值约 197,000 美元。最后，R Squared Ltd 在第二季度购买了 Pulmonx 的新股份，价值约 41,000 美元。91.04% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Pulmonx Stock Performance</h2>
<div class="lb-trans"><h2>Pulmonx 股票表现</h2>
</div><p>Shares of LUNG stock traded down $0.07 during mid-day trading on Wednesday, hitting $2.21. 482,764 shares of the stock were exchanged, compared to its average volume of 873,781. The stock has a market capitalization of $91.16 million, a price-to-earnings ratio of -1.57 and a beta of 0.22. Pulmonx has a 12-month low of $1.31 and a 12-month high of $9.37. The stock's fifty day simple moving average is $1.96 and its two-hundred day simple moving average is $2.04. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86.</p>
<div class="lb-trans"><p>LUNG 股票在周三的中午交易中下跌 0.07 美元，报 2.21 美元。该股票交易量为 482,764 股，而其平均交易量为 873,781 股。该股票的市值为 9116 万美元，市盈率为-1.57，贝塔系数为 0.22。Pulmonx 的 12 个月低点为 1.31 美元，12 个月高点为 9.37 美元。该股票的 50 日简单移动平均线为 1.96 美元，200 日简单移动平均线为 2.04 美元。公司的债务与股本比率为 0.62，速动比率为 4.15，流动比率为 4.86。</p>
</div><p>Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. The business had revenue of $21.50 million during the quarter, compared to the consensus estimate of $20.78 million. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%. On average, analysts forecast that Pulmonx will post -1.55 EPS for the current year.</p>
<div class="lb-trans"><p>Pulmonx (NASDAQ:LUNG - 获取免费报告) 最近在 11 月 12 日发布了季度财报。公司报告每股收益为-0.34 美元，超出市场共识预期的-0.40 美元 0.06 美元。该季度的营业收入为 2150 万美元，而市场共识预期为 2078 万美元。Pulmonx 的股本回报率为-77.58%，净利润率为-61.91%。分析师平均预测 Pulmonx 在本年度的每股收益为-1.55 美元。</p>
</div><h2>About Pulmonx</h2>
<div class="lb-trans"><h2>关于 Pulmonx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company's flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.</p>
<div class="lb-trans"><p>Pulmonx Corporation 是一家商业阶段的医疗设备公司，专注于为严重肺气肿患者提供支气管镜肺容积缩小治疗。公司的旗舰疗法 Zephyr®支气管阀系统采用单向阀，通过微创的支气管镜手术将其送入，以塌陷病变的肺部，减少肺部过度膨胀并改善呼吸功能。作为该治疗的补充，Pulmonx 还提供 Chartis®肺部评估系统，为临床医生提供定量的侧支通气测量，以帮助患者选择并优化临床结果。</p>
</div><p>The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.</p>
<div class="lb-trans"><p>Zephyr 阀在 2008 年获得欧洲 CE 标志，2018 年获得美国 FDA 批准，至今已被北美和欧洲的领先呼吸和胸外科中心采用。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Pulmonx</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Pulmonx</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微小的 “3 美元 AI 奇迹股” 即将爆发</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pulmonx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Pulmonx 吗？</h2>
</div><p>Before you consider Pulmonx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Pulmonx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Pulmonx 并不在名单上。</p>
</div><p>While Pulmonx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pulmonx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pulmonx 公司（NASDAQ:LUNG）空头头寸更新